Utility of accessible SARS-CoV-2 specific immunoassays in vaccinated adults with a history of advanced HIV infection
© 2024. The Author(s)..
Accessible SARS-CoV-2-specific immunoassays may inform clinical management in people with HIV, particularly in case of persisting immunodysfunction. We prospectively studied their application in vaccine recipients with HIV, purposely including participants with a history of advanced HIV infection. Participants received one (n = 250), two (n = 249) or three (n = 42) doses of the BNT162b2 vaccine. Adverse events were documented through questionnaires. Sample collection occurred pre-vaccination and a median of 4 weeks post-second dose and 14 weeks post-third dose. Anti-spike and anti-nucleocapsid antibodies were measured with the Roche Elecsys chemiluminescence immunoassays. Neutralising activity was evaluated using the GenScript cPass surrogate virus neutralisation test, following validation against a Plaque Reduction Neutralization Test. T-cell reactivity was assessed with the Roche SARS-CoV-2 IFNγ release assay. Primary vaccination (2 doses) was well tolerated and elicited measurable anti-spike antibodies in 202/206 (98.0%) participants. Anti-spike titres varied widely, influenced by previous SARS-CoV-2 exposure, ethnicity, intravenous drug use, CD4 counts and HIV viremia as independent predictors. A third vaccine dose significantly boosted anti-spike and neutralising responses, reducing variability. Anti-spike titres > 15 U/mL correlated with neutralising activity in 136/144 paired samples (94.4%). Three participants with detectable anti-S antibodies did not develop cPass neutralising responses post-third dose, yet displayed SARS-CoV-2 specific IFNγ responses. SARS-CoV-2 vaccination is well-tolerated and immunogenic in adults with HIV, with responses improving post-third dose. Anti-spike antibodies serve as a reliable indicator of neutralising activity. Discordances between anti-spike and neutralising responses were accompanied by detectable IFN-γ responses, underlining the complexity of the immune response in this population.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Scientific reports - 14(2024), 1 vom: 09. Apr., Seite 8337 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ferrari, Ludovica [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies |
|---|
| Anmerkungen: |
Date Completed 11.04.2024 Date Revised 12.04.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41598-024-58597-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370838009 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370838009 | ||
| 003 | DE-627 | ||
| 005 | 20240412233328.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240410s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41598-024-58597-4 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1373.xml |
| 035 | |a (DE-627)NLM370838009 | ||
| 035 | |a (NLM)38594459 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ferrari, Ludovica |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Utility of accessible SARS-CoV-2 specific immunoassays in vaccinated adults with a history of advanced HIV infection |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.04.2024 | ||
| 500 | |a Date Revised 12.04.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a Accessible SARS-CoV-2-specific immunoassays may inform clinical management in people with HIV, particularly in case of persisting immunodysfunction. We prospectively studied their application in vaccine recipients with HIV, purposely including participants with a history of advanced HIV infection. Participants received one (n = 250), two (n = 249) or three (n = 42) doses of the BNT162b2 vaccine. Adverse events were documented through questionnaires. Sample collection occurred pre-vaccination and a median of 4 weeks post-second dose and 14 weeks post-third dose. Anti-spike and anti-nucleocapsid antibodies were measured with the Roche Elecsys chemiluminescence immunoassays. Neutralising activity was evaluated using the GenScript cPass surrogate virus neutralisation test, following validation against a Plaque Reduction Neutralization Test. T-cell reactivity was assessed with the Roche SARS-CoV-2 IFNγ release assay. Primary vaccination (2 doses) was well tolerated and elicited measurable anti-spike antibodies in 202/206 (98.0%) participants. Anti-spike titres varied widely, influenced by previous SARS-CoV-2 exposure, ethnicity, intravenous drug use, CD4 counts and HIV viremia as independent predictors. A third vaccine dose significantly boosted anti-spike and neutralising responses, reducing variability. Anti-spike titres > 15 U/mL correlated with neutralising activity in 136/144 paired samples (94.4%). Three participants with detectable anti-S antibodies did not develop cPass neutralising responses post-third dose, yet displayed SARS-CoV-2 specific IFNγ responses. SARS-CoV-2 vaccination is well-tolerated and immunogenic in adults with HIV, with responses improving post-third dose. Anti-spike antibodies serve as a reliable indicator of neutralising activity. Discordances between anti-spike and neutralising responses were accompanied by detectable IFN-γ responses, underlining the complexity of the immune response in this population | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a BNT162 Vaccine |2 NLM | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Antibodies |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 700 | 1 | |a Ruggiero, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Stefani, Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Benedetti, Livia |e verfasserin |4 aut | |
| 700 | 1 | |a Piermatteo, Lorenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Andreassi, Eleonora |e verfasserin |4 aut | |
| 700 | 1 | |a Caldara, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Zace, Drieda |e verfasserin |4 aut | |
| 700 | 1 | |a Pagliari, Matteo |e verfasserin |4 aut | |
| 700 | 1 | |a Ceccherini-Silberstein, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Jones, Christopher |e verfasserin |4 aut | |
| 700 | 1 | |a Iannetta, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Geretti, Anna Maria |e verfasserin |4 aut | |
| 700 | 0 | |a EVAN-COV Study Group |e verfasserin |4 aut | |
| 700 | 1 | |a Ansaldo, Lorenzo |e investigator |4 oth | |
| 700 | 1 | |a Bertoli, Ada |e investigator |4 oth | |
| 700 | 1 | |a Bonfante, Francesco |e investigator |4 oth | |
| 700 | 1 | |a Braccialarghe, Neva |e investigator |4 oth | |
| 700 | 1 | |a Checchi, Davide |e investigator |4 oth | |
| 700 | 1 | |a Compagno, Mirko |e investigator |4 oth | |
| 700 | 1 | |a De Simone, Giuseppe |e investigator |4 oth | |
| 700 | 1 | |a Geretti, Anna Maria |e investigator |4 oth | |
| 700 | 1 | |a Grelli, Sandro |e investigator |4 oth | |
| 700 | 1 | |a Meloni, Diletta |e investigator |4 oth | |
| 700 | 1 | |a Mulas, Tiziana |e investigator |4 oth | |
| 700 | 1 | |a Piermatteo, Lorenzo |e investigator |4 oth | |
| 700 | 1 | |a Sarmati, Loredana |e investigator |4 oth | |
| 700 | 1 | |a Teti, Elisabetta |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Scientific reports |d 2011 |g 14(2024), 1 vom: 09. Apr., Seite 8337 |w (DE-627)NLM215703936 |x 2045-2322 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2024 |g number:1 |g day:09 |g month:04 |g pages:8337 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41598-024-58597-4 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2024 |e 1 |b 09 |c 04 |h 8337 | ||